Costs related to antibiotics are the most important factors influencing hospital formulary decision-making, according to a new report.
Costs related to antibiotics are the most important factors influencing hospital formulary decision-making, according to a new report.
The top three factors influencing hospital formularies, according to Arlington Medical Resources, are antibiotic cost-related attributes such as drug price and administration cost, pathogen coverage, and efficacy.
Activity against drug-resistant Gram-negative (GN) pathogens leads all other drug attributes associated with pathogen coverage among the pharmacy and therapeutics (P&T) committee members surveyed for the report, “Hospital Formulary Insights: Anti-Infectives (US) 2013.”
“This finding is consistent with the increasing prevalence of drug-resistant GN infections and with the high unmet need for new therapies against these drug-resistant pathogens,” noted a statement from Arlington Medical Resources.
However, despite the availability of several effective anti-methicillin-resistant Staphylococcus aureus therapies, hospital pharmacy directors still consider activity against this pathogen to be an important driver of formulary selections.
The majority of P&T committee members surveyed say they are including Forest's Teflaro and Optimer's Dificid in their hospital formularies. However, prescribing of these agents is typically restricted. For antibiotics in development, most P&T members anticipate adding Cubist/Bayer's tedizolid to their hospital's formulary with restrictions, if approved by the FDA and priced similarly to linezolid.
"Our research suggests that the generic availability of linezolid is going to be a formidable challenge to tedizolid's formulary uptake, as cost-conscious P&T committees seek to minimize expenditures and perceived formulary redundancies," said Brenda Perez-Cheeks, PhD, Director of Infectious Diseases, Arlington Medical Resources. "However, focusing tedizolid messaging on areas where surveyed P&T committee members deem tedizolid to have important advantages over linezolid could encourage its placement on formularies and drive uptake."
Psychiatric Pharmacist Helping to Bridge the Care Gap for Patients With Mental Illness
October 24th 2024Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.